$21.030
-1.199 (-5.70%)Al cierre
Noticias de STVN
Eventos de STVN
Company Narrows 2026 Revenue View to EUR1.26B-EUR1.28B
Narrows 2026 revenue view to EUR1.26B-EUR1.28B from EUR1.26B-EUR1.29B.
Stevanato Reports Q2 Revenue of €302.0M
Reports Q2 revenue EUR302.0M vs. EUR280.0M last year. CEO Franco Stevanato commented, "Results were in line with our expectations with 8% topline growth driven by 10% growth at constant currency rates in our BDS Segment. We recently achieved a significant commercial milestone for our Drug Delivery Systems business and our proprietary DDS products. A customer recently received regulatory approval in several European countries for a liraglutide-based therapy that incorporates Stevanato Group's Alina pen injector platform. This important customer project also embeds our world-class cartridge technology into the Alina pen platform, harnessing the power of our integrated capabilities."
Stevanato Group Receives Marketing Authorization for Alina Injector in Europe
Stevanato Group announced that liraglutide-based combination products incorporating Stevanato Group's proprietary Alina pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders. The approved configurations include Alina 30, developed for liraglutide-based therapies for diabetes, and Alina 50, designed for liraglutide-based weight management applications. Both variants are part of Stevanato Group's broader Alina variable-dose pen injector platform, which offers multiple pre-configured variants for GLP-1s and other injectable therapies. Alina features a dial-a-dose mechanism with visual, audible, and tactile feedback during dose selection and injection, and compatibility with ISO standard 3 mL glass cartridges. The platform has been designed to support manufacturing scalability, and integration into existing pharmaceutical fill and finish and final assembly supply chains.
Morgan Stanley Rates Stevanato Group Equal Weight with $24 Price Target, Downgraded from $26
Morgan Stanley assumed coverage of Stevanato Group with an Equal Weight rating and a price target of $24, down from $26. Life Science Tools and Diagnostics end market bright spots are beginning to emerge and the firm sees "plenty of catalysts" in the pipeline across its coverage, adding that it sees "lots to like in the space entering 2026." However, a recent industry valuation spike in the second half of the year leaves multiples in "a fair place," so the firm starts the group with an In-Line industry view, the analyst tells investors. Among the group, the analyst identifies Danaher (DHR) as Top Pick.
Stevanato Group projects adjusted EPS of EUR0.50-EUR0.54 for 2025
Sees 2025 revenue EUR 1.16B-EUR1.19B.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.